UpToDate® : Oncology Times
An abstract is unavailable.
Related Articles
Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC
Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Plasma cell and cancer stem cell crosstalk in glioblastoma
Plasma cells (PCs) are the main producers of antibodies and have context-dependent roles in tumor immunity. In this issue of Cancer Cell, Gao et al. report…
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…
One Form to “Rule” Them All (and in the TM Bind Them) | SWOG
Our translational research generally builds on resources from our clinical trials, just as our clinical studies build on information learned from our translational research. We’re…
Investigating New Treatments for Rare Skin Lymphomas – News Center
A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of…
The Power of Preference Signaling: A Monumental Shift in… : JAAOS – Journal of the American Academy of Orthopaedic Surgeons
ng concern. With the implementation of the Preference Signaling Program, the total number of applications has now dropped for the first time in many years,…
Taking a Swing at TIMP1-Armed Immunosuppressive Astrocytes Unleashes T cell Immunity against Brain Metastases
Summary:. Priego and colleagues identify a secreted glycoprotein TIMP1, expressed downstream of the transcription factor STAT3, in a subpopulation of STAT3+ reactive astrocytes as a…
Combined targeted modality in cHL: a risky bet?
In this issue of Blood, Lee et al1 conclude that the brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (BV-N-AD) regimen shows a tolerable safet
Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma
Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.